Revolution Medicines pancreatic cancer drug advances toward second-line use

Daraxonrasib, a pancreatic cancer treatment developed by Revolution Medicines, is advancing toward adoption as the standard second-line therapy for the disease. The drug's progress was outlined in coverage published June 4, 2026. Attention has now turned to whether the treatment can be applied earlier in the disease course.

Next steps for the treatment Officials and researchers are examining data that could support use of the drug in patients who have not yet received prior therapy. The company has not released a timeline for additional studies. Further clinical work would be required before any change in approved use could occur.